B. Riley Predicts Harrow’s Q3 Earnings (NASDAQ:HROW)

Harrow, Inc. (NASDAQ:HROW) – Investment analysts at B. Riley raised their Q3 2025 earnings estimates for Harrow in a research report issued to clients and investors on Tuesday, September 23rd. B. Riley analyst M. Mamtani now expects that the company will earn $0.36 per share for the quarter, up from their prior estimate of $0.29. B. Riley currently has a “Buy” rating and a $70.00 price objective on the stock. The consensus estimate for Harrow’s current full-year earnings is ($0.53) per share. B. Riley also issued estimates for Harrow’s Q4 2025 earnings at $0.63 EPS and FY2026 earnings at $2.88 EPS.

Harrow (NASDAQ:HROW) last issued its earnings results on Monday, August 11th. The company reported $0.24 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.23. The company had revenue of $63.74 million for the quarter, compared to analysts’ expectations of $64.23 million. Harrow had a negative net margin of 4.49% and a negative return on equity of 2.18%. Harrow has set its FY 2025 guidance at EPS.

A number of other equities analysts have also commented on HROW. Zacks Research lowered shares of Harrow from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 12th. HC Wainwright boosted their price objective on Harrow from $60.00 to $64.00 and gave the stock a “buy” rating in a report on Wednesday, August 13th. William Blair started coverage on Harrow in a research note on Tuesday, June 10th. They set an “outperform” rating for the company. Craig Hallum increased their price objective on Harrow from $54.00 to $64.00 and gave the company a “buy” rating in a report on Tuesday. Finally, BTIG Research reiterated a “buy” rating and set a $63.00 price objective on shares of Harrow in a research report on Wednesday. Seven analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, Harrow presently has an average rating of “Moderate Buy” and an average price target of $65.33.

Harrow Stock Performance

NASDAQ:HROW opened at $46.15 on Thursday. Harrow has a twelve month low of $20.85 and a twelve month high of $59.23. The company has a 50-day moving average of $38.25 and a 200-day moving average of $31.21. The firm has a market cap of $1.71 billion, a price-to-earnings ratio of -184.60 and a beta of 0.33. The company has a current ratio of 0.62, a quick ratio of 0.58 and a debt-to-equity ratio of 0.78.

Institutional Investors Weigh In On Harrow

A number of hedge funds have recently added to or reduced their stakes in HROW. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Harrow by 89.5% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 61,940 shares of the company’s stock worth $2,078,000 after buying an additional 29,262 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Harrow by 2,401.2% during the 1st quarter. GAMMA Investing LLC now owns 6,278 shares of the company’s stock valued at $1,670,000 after buying an additional 6,027 shares during the last quarter. HighTower Advisors LLC lifted its position in shares of Harrow by 30.5% during the 1st quarter. HighTower Advisors LLC now owns 13,217 shares of the company’s stock valued at $352,000 after buying an additional 3,090 shares during the last quarter. Voya Investment Management LLC lifted its position in shares of Harrow by 4,035.5% during the 1st quarter. Voya Investment Management LLC now owns 381,461 shares of the company’s stock valued at $10,147,000 after buying an additional 372,237 shares during the last quarter. Finally, Rhumbline Advisers lifted its position in shares of Harrow by 7.2% during the 1st quarter. Rhumbline Advisers now owns 42,975 shares of the company’s stock valued at $1,143,000 after buying an additional 2,879 shares during the last quarter. 72.76% of the stock is currently owned by institutional investors.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.